# Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

> **NCT01367275** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Colorectal Cancer
- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Brivanib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01367275
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor closed study
- **Last updated:** 2020-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01367275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01367275, "Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01367275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*